Italia markets closed

Dow Jones
39.828,79
+270,68(+0,68%)
Nasdaq
16.728,02
+216,84(+1,31%)
Nikkei 225
38.385,73
+29,67(+0,08%)
EUR/USD
1,0877
+0,0055(+0,51%)
Bitcoin EUR
60.062,17
+3.629,50(+6,43%)
CMC Crypto 200
1.373,32
+105,37(+8,31%)

NVCR Jun 2024 17.500 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

4,0200

+0,5900

(+17,20%)

In data: 12:02PM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in